Skip to main content
Clinical Trials/NCT02898987
NCT02898987RecruitingNot Applicable

Dataids Prospective Observational Cohort on Quality of Care of French HIV Infected Patients

DatAids39 sites in 3 countries30,000 target enrollmentStarted: January 1, 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
30,000
Locations
39
Primary Endpoint
Proportion of HIV treated patients with HIV plasma viral load < 50 copies/mL

Study Overview

Brief Summary

The objective of the Dataids cohort is to continue a long-term, prospective collection of clinical, laboratory and therapeutic data on a large cohort of HIV infected patients seeking care in 15 HIV centers in France in order :

  1. to provide and develop a surveillance system to describe clinical practice and temporal changes in the clinical course of HIV and HIV-related co-infections and co-morbidities in France.
  2. to assess the factors associated with the clinical, immunological and virological course of HIV infection and HIV-related co-infections and co-morbidities

The specific objectives are as follows

  • To continue surveillance of HIV infection in France to describe temporal changes
  • To evaluate the efficacy of ART and factors associated with ART efficacy
  • To monitor the uptake and outcome of HCV therapy

Detailed Description

The Dataids cohort is a prospective observational cohort of 30,000+ patients followed in 15+ HIV centers scattered throughout France. The Dataids cohort is an ongoing collaboration and patients have been enrolled into the study since 2010; the data are collected from the clinics as part of routine care. Included patients should be patients who had a scheduled visit in the outpatient clinic regardless of CD4 cell count, HIV viral load or ART status. For all HIV patients enrolled and under follow up, demographic data, immunological and virological data, serological evidence for infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis, laboratory, therapeutic and clinical data are collected annually.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • HIV-1 infected patients regardless of CD4 cell count and antiretroviral therapy status

Exclusion Criteria

  • Patients under 18 years of age
  • Patients without written informed consent

Outcomes

Primary Outcomes

Proportion of HIV treated patients with HIV plasma viral load < 50 copies/mL

Time Frame: From date of enrollment, through study completion, an average of 6 months

Secondary Outcomes

  • Proportion of HIV/HCV coinfected patients who start treatment with direct acting antivirals agents(From date of enrollment, through study completion, an average of 1 year)
  • proportion of HIV/HCV patients with undetectable HCV viral load after treatment with direct acting antivirals agents(From date of enrollment, through study completion, an average of 1 year)
  • Proportion of HIV patients according to their antiretroviral status : naive, on treatment, therapeutic stop(From date of enrollment, through study completion, an average of 1 year)
  • Proportion of HIV patients with CD4 cells count above 500 /ml(From date of enrollment, through study completion, an average of 1 year)
  • Incidence of aids events among patients enrolled in the cohort study(From date of enrollment, through study completion, an average of 1 year)
  • Incidence of non aids events among patients enrolled in the cohort study(From date of enrollment, through study completion, an average of 1 year)
  • Incidence of antiretroviral modification due to simplification or failure(From date of enrollment, through study completion, an average of 1 year)

Investigators

Sponsor
DatAids
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (39)

Loading locations...

Similar Trials